Distribution, clearance, and mortality of environmental pseudomonads in mice upon intranasal exposure.

When introduced intranasally, P. cepacia AC1100 (approximately 10(8) CFU/animal) and P. aeruginosa AC869 (approximately 10(3) CFU/animal) were readily cleared from the mouse. However, a approximately 10(7)-CFU dose of AC869 persisted for 14 days. Strain AC869 had a 50% lethal dose of 2.7 x 10(7) CFU. Slight morbidity occurred in animals treated with approximately 10(7) CFU of AC869 or approximately 10(8) CFU of AC1100.

Influence of antibiotics on intestinal tract survival and translocation of environmental Pseudomonas species.

The environmental release of microorganisms has prompted the investigation of potential health effects associated with their release. In this study, survival and translocation to the spleen and liver of several environmental Pseudomonas spp. were investigated in antibiotic-treated mice. Pseudomonas aeruginosa BC16 and P. maltophilia BC6, isolated from a commercial product for polychlorinated biphenyl degradation; P. aeruginosa AC869, a 3,5-dichlorobenzoate degrader; and P. cepacia AC1100, an organism that metabolizes 2,4,5-trichlorophenoxyacetic acid were examined for their survival capabilities in the intestines of mice dosed with clindamycin, kanamycin, rifampin, or spectinomycin. A mouse intestinal isolate, strain PAMG, was included in the study. Following antibiotic pretreatment (1 mg twice daily for 3 days), mice were dosed by gavage with 10(9) CFU of each Pseudomonas strain. At the end of the 5-day test period, strains AC869 and PAMG survived in kanamycin-, rifampin-, spectinomycin-, and clindamycin-treated animals. A statistically significant (P less than 0.05) increase in survival of strain PAMG was observed in clindamycin-, kanamycin-, and spectinomycin-treated mice for the test period. Treatment with clindamycin or rifampin increased (P less than 0.05) survival of strain BC6, an organism resistant to both antibiotics. However, strain BC6 was detected only in rifampin-treated mice at the end of the 5-day test period. Strain BC16, a clindamycin-resistant strain, was detected in clindamycin-treated mice and the untreated control animals. Rifampin had a negative effect (P less than 0.05) on strain AC869 and PAMG survival. Translocation to the spleen was observed in spectinomycin- and clindamycin-treated mice but was not detected in kanamycin- or rifampin-treated animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Saturation of lindane metabolism in chronically treated (YS x VY) F1 hybrid mice.

The organochlorine insecticide lindane (gamma-hexachlorocyclohexane) induces hepatomas in select strains of mice including two of three phenotypic classes of (YS X VY) F1 hybrid mice. In contrast, lindane does not induce hepatomas in rats and other strains of mice. It has been suggested that variations in the biotransformation of lindane may play a role in the different susceptibility of rodents to lindane-induced hepatomas. This study reports the effect of chronic treatment with 160 ppm dietary lindane on the comparative metabolism and disposition of this insecticide in obese yellow Avy/a, lean pseudoagouti Avy/a, and lean black a/a phenotypes of (YS X VY) F1 hybrid female mice at 17, 30, 56, and 86 wk of age. At 24 h prior to necropsy, all mice were dosed po with 18 mg lindane (containing 55 muCi [U-14C]lindane)/kg. Urine, feces, and expired air were sampled for analysis. Data indicated that metabolism of lindane and excretion of its metabolites by these mice differ significantly from those of rats that are resistant to lindane-induced hepatomas. Treatment of the mice with 160 ppm lindane in the diet appeared to saturate the elimination pathways and resulted in an increased tissue burden of the insecticide and its metabolites in the older animals. Results indicate that differences in lindane metabolism and disposition observed in the (YS X VY) F1 hybrid mice were associated with chronic lindane treatment, aging, and obesity but not with genotype.

Use of gamma-hexachlorocyclohexane (lindane) to determine the ontogeny of metabolism in the developing rat.

The compound lindane (gamma-hexachlorocyclohexane) has been used to study the ontogeny of metabolism in the developing Fischer 344 rat. The distribution and metabolic fate of lindane at 2, 9, 16, and 23 d of age was investigated following subcutaneous administration of lindane at 20 mg/kg containing 0.5 microCi [U-14C]lindane in peanut oil. Groups of 10 pups (5 male and 5 female) were sacrificed at 4-h intervals during the 24-h period following dosing. Adrenals, blood, brain, heart, lung, liver, and kidneys were analyzed for radioactivity. Urine samples were analyzed for radioactivity and metabolites of lindane. There was a significant age-dependent increase in the metabolism of lindane in the rat. High levels of radioactivity in the lung and increased reductive dechlorination suggest that the lung may play a greater role in metabolism of lindane by young rats. Oxidative phase I reactions increased significantly, while anaerobic reductive dechlorination of lindane to 4-chlorophenylmercapturic acid decreased significantly with age. Phase II sulfate and glutathione conjugations decreased significantly and glucuronide conjugation increased significantly with age. Metabolism and excretion of lindane appear to parallel development of the hepatic enzymes involved in phase I and phase II reactions.

Effects of age and obesity on the metabolism of lindane by black a/a, yellow Avy/a, and pseudoagouti Avy/a phenotypes of (YS x VY) F1 hybrid mice.

Lindane (gamma-hexachlorocyclohexane) has been shown to produce hepatomas in some strains of mice but not in others. Genetic factors and/or altered metabolism may play a role in the susceptibility to lindane-induced hepatomas. This study reports the effect of age and obesity on the comparative metabolism and disposition of lindane in obese yellow Avy/a and in lean pseudoagouti Avy/a and black a/a phenotypes of (YS x VY) F1 hybrid female mice at 8, 17, 30, 56, and 86 wk of age. At 24 h prior to sacrifice the mice were dosed p.o. with 18 mg lindane (containing 55 microCi [U-14C]lindane/kg). Aging altered the biotransformation of lindane such that while the excretion of lindane and its metabolites declined, the proportion of conjugated and polar metabolites increased. Tissue storage was elevated in older animals. In the yellow Avy/a mice, which are known to have a predisposition to the formation of hepatomas, there was accelerated and prolonged growth, reduced metabolite excretion, a greater proportion of conjugated metabolites, and higher dechlorinase activity compared to that of their pseudoagouti Avy/a and black a/a siblings.

Electrocardiographic studies of developing rodents exposed in utero to trypan blue.

Techniques, based on computer-assisted analyses of ensembled ECG waveforms, have been developed in this laboratory to serve as a screening procedure for potentially cardiotoxic substances. This procedure was tested on fetal and neonatal rats exposed in utero to two levels of trypan blue, a known cardiovascular teratogen. The offspring of the treated animals exhibited decreased viability, as well as significant levels of both cardiac and noncardiac malformations. Qualitative assessment of ECG irregularities demonstrated an increased number of abnormalities in the treated groups. Correlations were also obtained between observed morphological defects and ECG irregularities in the trypan blue treated groups.

Perinatal toxicity of endrin in rodents. I. Fetotoxic effects of prenatal exposure in hamsters.

The potential of the insecticide endrin to induce fetal toxicity was determined in hamsters exposed to the compound on either day 8 or days 5--14 of gestation. Endrin was administered by oral gavage as a solution in corn oil. Doses used included 0.5--10.0 mg/kg on day 8 and 0.75 to 3.5 mg/kg/day on days 5--14. Exposure to a single dose of endrin resulted in significant incidences of fused ribs and meningoencephaloceles at levels of 5 mg/kg or greater. No significant effects were noted in either maternal mortality and weight gain or in fetal mortality or weight gain. The administration of multiple doses of endrin resulted in few fetal defects, although a significant dose-related increase in fetal mortality and decrease in fetal weight was seen. Significant maternal lethality and weight reductions were noted at doses of 1.5 mg/kg/day or greater. At sacrifice, maternal liver and fetal tissues were collected and subsequently analyzed for endrin and a major metabolite, 12-ketoendrin. Endrin was found to cross the placenta and 20 ppb were found in fetuses from litters exposed to 2.5 mg/kg/day. Maternal livers from this dose group contained an average of 2500 pbb of endrin.